KORU Medical Systems Inc

KORU Medical Systems, Inc. engages in the design, manufacture, and market of proprietary medical devices. Its product portfolio includes FREEDOM60, FreedomEdge syringe drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets. The company was founded by Andrew I. Sealfon and Adrian W. Zorgniotti on March 24, 1980 and is headquartered in Mahwah, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

KORU Medical Systems reports robust Q4 growth and eyes international expansion

KORU Medical Systems demonstrated strong financial performance in Q4 2022, with revenue growth and cash position exceeding expectations.
The company's strategic focus on novel therapies and international expansion presents growth opportunities, though margin improvement and market challenges remain.
With a clear Vision 26 strategy and positive revenue guidance for 2023, KORU is poised for continued growth and market leadership.

KORU Medical Systems excels in Q1 2023, poised for strategic growth

KORU Medical Systems delivered a robust performance in Q1 2023, showcasing growth across key business segments and strategic initiatives.
The company's focus on revenue targets, margin improvement, and operational efficiency positions it well for future success.
While challenges like managing cash burn and market dynamics exist, KORU's strengths in product leadership and financial management offer resilience.
Strategic opportunities in market expansion, innovation, and customer value creation provide a positive outlook for the company's growth trajectory.

KORU Medical Systems reports Q2 growth, projects improved margins

KORU Medical Systems demonstrated overall growth in Q2 2023, driven by strong performance in core businesses and improving gross margins. While facing challenges in Novel Therapies and a net cash operating loss, the company remains optimistic about future revenue growth and strategic initiatives.

KORU Medical Systems Inc reports Q3 revenue decline, focuses on margin expansion and Novel Therapies collaborations

KORU Medical Systems Inc faces revenue challenges but focuses on margin expansion, expense control, and strategic investments. The company aims for cash flow breakeven by Q4 2024, emphasizing Novel Therapies business and market growth assumptions.

KORU Medical Systems reports solid Q4 growth and outlines expansion plans for 2024

KORU Medical Systems' Q4 2023 performance reflects steady growth and strategic advancements in product development and market expansion. While facing challenges in production efficiency and European certification, the company is well-positioned to capitalize on opportunities in prefilled syringes and novel therapies for future growth.

KORU Medical Systems achieves record revenue and eyes global expansion

KORU Medical Systems delivered strong Q1 2024 results with record revenue and gross margin, alongside reduced cash burn.
The company reaffirmed guidance, secured new collaborations, and expanded internationally, while facing regulatory approval challenges.
Opportunities lie in FDA approvals, cash flow targets, and sustained U.S. core business growth through innovations and partnerships.

KORU Medical Systems excels in Q3, eyes growth opportunities

KORU Medical Systems delivered robust financial performance in Q3 2024, with raised revenue guidance and expectations of cash flow positivity in 2025.
The company's strategic focus on new product development and market expansion positions it well for sustained growth and profitability.
While facing challenges in maintaining growth momentum and operational efficiency, KORU's strong performance and outlook signal a promising future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adicet Bio, Inc.

Arbe Robotics Ltd

Lantronix

CarParts.com, Inc.

PowerFleet Inc

Vor Biopharma

In most cases, investors should stay away from penny stocks. They're wild, they're unpredictable and they tend to lose their stakeholders money more so than they return.

The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, is pleased to announce data on the impact of the Freedom Infusion System on subcutaneous immunoglobulin (SCIg) therapy for primary immunodeficiency diseases (PIDD) to be presented at the National Home Infusion Ass.

KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference

KORU Medical Systems, Inc. (KRMD) Q4 2023 Earnings Call Transcript

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the fourth quarter and full year ended December 31, 2023. The Company also issued guidance for the full year 2024. Recent Highlights Fourth quarter 2023 net revenues of $7.2 mi.

KORU Medical Systems, Inc. Announces 2023 Fourth Quarter, Full Year Financial Results, and 2024 Guidance

One key aspect of the collaboration of KORU Medical (KRMD) with a pharmaceutical manufacturer is the exploration of new therapeutic settings.

KORU Medical (KRMD) Forms New Deal on Subcutaneous Infusion

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a collaboration with a global pharmaceutical manufacturer to initiate a feasibility study with KORU's Freedom Infusion System for an already commercialized rare disease therapy. Upon successful com.

KORU Medical Systems Announces a Feasibility Study to Enter Ambulatory Infusion Settings with a Commercialized Biologic

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, is pleased to announce a clinical supply agreement for a novel subcutaneous immunoglobulin (SCIg) drug entering Phase 3 trials. The custom product developed for this clinical trial under a prior agreement was buil.

KORU Medical Systems Signs a Clinical Supply Agreement for Phase 3 Trial with Leading Pharma Partner Using Custom Device for a Novel Subcutaneous Immunoglobulin

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients, today announced that the Company will report fourth quarter and full year 2023 financial results on Wednesday, March 13, 2024. KORU Medical's management will host a conference call and webca.

KORU Medical Systems to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients, today announced that the Company will participate in Piper Sandler's 35th Annual Healthcare Conference on November 29, 2023. KORU Medical's management is scheduled to present at Piper San.

KORU Medical Systems to Participate in Piper Sandler's 35th Annual Healthcare Conference

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced it will host an investor day at the Mahwah, NJ headquarters on Tuesday, December 5, 2023, from 10:00 a.m. to 12:00 p.m. Eastern Time. The event will include p.

KORU Medical Systems, Inc. to Host Investor Day on December 5, 2023

KORU Medical Systems, Inc. (NASDAQ:KRMD ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Linda Tharby - Chief Executive Officer and President, Director Tom Adams - Chief Medical Officer Conference Call Participants Caitlin Cronin - Canaccord Genuity Joseph Downing - Piper Sandler Frank Takkinen - Lake Street Capital Operator Good day. And welcome to the KORU Medical Systems Third Quarter 2023 Earnings Call.

KORU Medical Systems, Inc. (KRMD) Q3 2023 Earnings Call Transcript

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced a development agreement with a biopharmaceutical manufacturer for KORU Medical to develop and seek regulatory approval for a next-generation infusion system f.

KORU Medical Systems, Inc. Announces Development Agreement for Next-generation Subcutaneous Immunoglobulin Infusion System

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Ken Miller as Chief Commercial Officer, effective November 6, 2023. Ken brings over 30 years of extensive expertise and experience in leadi.

KORU Medical Systems, Inc. Appoints Ken Miller as Chief Commercial Officer

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today reported financial results for the third quarter ended September 30, 2023 and updates full year 2023 outlook. Highlights: Third quarter net revenue of $7.0 million, a 10% decline ve.

KORU Medical Systems, Inc. Announces 2023 Third Quarter Financial Results and Updates Full Year 2023 Outlook

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced that it received U.S. Food and Drug Administration (FDA) clearance for use of the FREEDOM60® Infusion System with Hizentra® 50 mL prefilled syringes (PFS). “B.

KORU Medical Systems, Inc. Receives FDA 510(k) Clearance for FREEDOM60® Infusion System With Hizentra® 50 ML Prefilled Syringes

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients, today announced that the Company will report third quarter 2023 financial results on Wednesday, November 8, 2023. KORU Medical's management will host a conference call and webcast at 4:30 p.

KORU Medical Systems to Report Third Quarter Financial Results on November 8, 2023

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, is pleased to announce its participation in the Immunoglobulin National Society (“IGNS”) 2023 National Conference, taking place in Denver, Colorado from October 5th to 8th. K.

KORU Medical Systems to Present Two Abstracts at the Immunoglobulin National Society 2023 National Conference

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced that Edward Wholihan was appointed to the Company's Board of Directors on September 28, 2023 to fill the vacancy that followed the Company's 2023 Annual Meeti.

KORU Medical Systems, Inc. Announces Appointment of Edward Wholihan to Its Board of Directors

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients, today announced that the Company will participate in the Gilmartin Group Emerging Growth Company Showcase on September 21, 2023. KORU Medical's management is scheduled to present at the Gilm.

KORU Medical Systems to Participate in the Gilmartin Group Emerging Growth Company Showcase

KORU Medical Systems, Inc. (NASDAQ:KRMD ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Linda Tharby - President and CEO Tom Adams - Chief Medical Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Caitlin Cronin - Canaccord Genuity Operator Greetings and welcome to the KORU Medical Systems Second Quarter 2023 Financial Results Conference Call and Webcast. At this time, all participants are in listen-only mode.

KORU Medical Systems, Inc. (KRMD) Q2 2023 Earnings Call Transcript

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today reported financial results for the second quarter ended June 30, 2023 and updates full year 2023 outlook. Highlights: Second quarter net revenue growth versus prior year of 6% to $6.

KORU Medical Systems, Inc. Announces 2023 Second Quarter Financial Results and Updates Full Year 2023 Outlook

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients, today announced that the Company will participate in the Canaccord Genuity 43rd Annual Growth Conference on August 10, 2023. KORU Medical's management is scheduled to present at the Canaccor.

KORU Medical Systems to Participate in the Genuity 43rd Annual Growth Conference

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced preliminary unaudited revenues for the second quarter 2023 and provided business, outlook and executive updates. The Company reported total net revenues for t.

KORU Medical Systems, Inc. Announces Preliminary Second Quarter 2023 Revenues and Provides Business, Outlook and Executive Updates

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients, today announced that the Company will report second quarter 2023 financial results on Wednesday, August 9, 2023. KORU Medical's management will host a conference call and webcast at 4:30 p.m.

KORU Medical Systems to Report Second Quarter Financial Results on August 9, 2023

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use subcutaneous infusion solutions, today announced an agreement with a biopharmaceutical company to validate its FREEDOM™ Infusion System for use with the biopharma company's drug, a novel biologic. Under terms of the Agreement, Koru Medical will validate the Freedom Infusion System for use with th.

News for KORU Medical Systems Inc Stock (KRMD)